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Abstract
Melanoma is the most aggressive form of skin cancer, and its incidence has increased dramatically over the years.
The murine B16F10 melanoma in syngeneic C57Bl/6 mice has been used as a highly aggressive model to inves-
tigate tumor development. Presently, we demonstrate in the B16F10-Nex2 subclone that silencing of SOCS-1, a
negative regulator of Jak/Stat pathway, leads to reversal of the tumorigenic phenotype and inhibition of melanoma
cell metastasis. SOCS-1 silencing with short hairpin RNA affected tumor growth and cell cycle regulation with
arrest at the S phase with large-sized nuclei, reduced cell motility, and decreased melanoma cell invasion through
Matrigel. A clonogenic assay showed that SOCS-1 acted as a modulator of resistance to anoikis. In addition, down-
regulation of SOCS-1 decreased the expression of epidermal growth factor receptor (mainly the phosphorylated-R),
Ins-Rα, and fibroblast growth factor receptor. In vivo, silencing of SOCS-1 inhibited subcutaneous tumor growth
and metastatic development in the lungs. Because SOCS-1 is expressed in most melanoma cell lines and bears a
relation with tumor invasion, thickness, and stage of disease, the present results on the effects of SOCS-1 silencing in
melanoma suggest that this regulating protein can be a target of cancer therapy.
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Introduction
Malignant melanoma is the most invasive and deadly skin cancer
with increasing incidence [1,2]. Tumor cell induction, invasion,
and metastasis have been intensely studied, and numerous receptors,
mediators, and signaling pathways have been identified [3,4]. The
understanding of the regulatory pathways involved in melanoma devel-
opment and progression has advanced significantly in recent years [5].
Among these pathways, those involving Ras, B-Raf, MEK, PTEN,
phosphatidylinositol-3 kinase, and Akt are constitutively activated in
melanoma [6]. The Ras-Raf-MEK 1, 2–ERK 1, 2 cascade is activated
by growth factors and has been implicated in cell proliferation, differ-
entiation, and survival [7]. Another signaling pathway activated by
growth factor receptors involves the phosphorylation of signal trans-
ducers and activators of transcription (STAT).
The JAK/STAT pathways have been implicated in tumor promotion,
migration, and invasive growth [8–12]. Pleiotropic STATs in these path-
ways are negatively regulated by suppressor of cytokine signaling
(SOCS) proteins [13–15]. There are eightmembers in the SOCS family
(CIS and SOCS 1-7). Each one has a central SH2 domain, an amino-
terminal domain of variable length and sequence, and a 40–amino acid
module on the carboxy-terminal region that is known as the SOCS box
[16]. The SOCS boxmediates interactionwith elongin B andC, cullin-5,
and RING-box-2 (RBX2), which recruits E2 ubiquitin transferase [17].
The SOCS family of proteins as well as other SOCS-box–containing
molecules, probably functions as E3 ubiquitin ligases and facilitates the
degradation of proteins that are associated with members of this family
through their N-terminal regions. The SOCS-1 expression product,
focused on in the present work, interacts with themicrotubule organizing
complex and may target JAKs [18].
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SOCS-1 suppresses the cellular response to various cytokines includ-
ing interleukin-6 (IL-6), IL-4, leukemia inhibitor factor, oncostatin M,
interferon (IFN), and growth hormones. The main regulatory function
of SOCS-1 is to inhibit cytokine signal transduction through direct
interaction with active JAK-2 by binding to their activation loop
through its SH2 domain [19]. In fact, many studies have demonstrated
the role of SOCS protein on cytokine signaling, including the immune
suppression and cytokine resistance [20–22]. In relation to tumor cells,
studies have focused on the tumor response to cytokines as a function of
SOCS protein expression. Zitzmann et al. [22] showed that silencing of
SOCS-1 expression by small interfering RNA (siRNA) enhanced the
antitumor effects of type I IFNs on neuroendocrine tumor cells.
Down-regulation of basal Bcl-2 and Bcl-xL and up-regulation of basal
Bak and Bax accompanied silencing of SOCS-1. The antiproliferative
effect of IFN-β and IFN-γ was also shown in tumor cells on silencing
of SOCS-1 [23]. In human melanoma, siRNA inhibition of SOCS-1
and SOCS-3 expression enhanced their responsiveness to IFN-α and
IFN-γ stimulation [24], and the progression of melanoma cells from
IFN-γ sensitivity to IFN-γ resistance was associated with attenuation of
SOCS genes induction and constitutive expression of SOCS-3 [25]. Li
et al. [26] showed that normal and transformed human melanocyte cells
constitutively express SOCS-1 transcripts in vitro, whereas the SOCS-1
protein was found only in melanoma cells. In contrast, Yoshikawa et al.
[21] showed that SOCS-1 protein acted as a tumor suppressor gene in
hepatocellular carcinoma cells. Thus, the role of SOCS-1 in tumor
development and progression seems to be cell type–specific, with
SOCS-1 acting either as a tumor suppressor gene or as a marker of pro-
gression in melanoma [27,28].
In the present study, we examined the short hairpin RNAi (shRNAi)
silencing of SOCS-1 in B16F10-Nex2 melanoma cells to address
the mechanisms governing development and progression of mela-
noma and to evaluate the SOCS-1 protein as a promising target for
cancer therapy.
Materials and Methods
Cell Lines and Stable Transduction
B16F10 murine melanoma cells were originally obtained from the
Ludwig Institute for Cancer Research in São Paulo. Different sublines
(Nex) were isolated at the Experimental Oncology Unit (UNONEX)
with different characteristics including the serum source used for
in vitro subculturing [29]. The subline B16F10-Nex2 with medium
invasiveness capacity in vivo was presently used. Cell lines were the
B16F10-Nex2 clone (B16), the cell line transduced with the empty
(control) lentivirus vector (B16 LVc), and the cell line transduced
with the shRNAi SOCS-1 construction (B16 shR-SOCS-1). They
were cultured in RPMI-1640 supplemented with 10 mM HEPES,
24 mM sodium bicarbonate, 40 mg/ml gentamicin, and 10% fetal
calf serum (FCS), pH 7.4, at 37°C and 5% CO2.
Plasmid, Transduction, and Transfection
For stable silencing of the SOCS-1 gene, we generated lineages with
the specific construction. Plasmid pLKO.1 (Addgene, Cambridge, MA)
and the annealed insert corresponding to the shRNAi for SOCS-1 gene
were cleaved at cloning sites with restriction enzymes AgeI and EcoRI
(Invitrogen, San Diego, CA). The insert was then ligated into the plas-
mid and transformed into Escherichia coli strain DH5α with ampicillin
resistance gene. The sequences of SOCS-1 sense and antisense oligo-
nucleotides used were described by Takahashi et al. [23], with modi-







To expand the plasmid, DH5α bacteria were transformed by heat
shock with the vectors, which were purified by mini-prep or maxi-prep
alkaline. The plasmid was then sequenced at the Center for Human
Genome Studies (São Paulo, Brazil), 350 ng/ml by sample using
MegaBACE 1000 (GE Healthcare, Piscataway, NJ). The sequencing
reactions were performed according to the MegaBACE 1000 proto-
col using the DYEnamic ET Dye Terminator Kit (with Thermo Se-
quenase II DNA polymerase; GE Healthcare) code US81090. The
sequences were analyzed with the Sequence Analyser software (GE
Healthcare) using the Base Caller Cimarron 3.12 (GE Healthcare).
The recombinant lentivirus was produced by transfecting HEK 293
cells with the pLKO vector, MD2G packaging plasmid, and PAX2
envelope plasmid (Addgene) as described below. The B16F10-Nex2
cells were seeded in six-well plates (5 × 105 cell/well) and, 16 hours later,
transduced with the virus at a multiplicity of infection of 5. After cell
transduction with the control pLKO virus, the population of puromycin-
resistant cells was selected.
Construction of the Lentiviral Particle shRNAi SOCS-1
The synthesis of viral particles was performed following the manu-
facturer’s instruction (Addgene). The first step was to transfect HEK-
293 cells (human kidney) with a mixture of plasmids, each imprinting a
particular structural feature in the viral particle. Thus, 1 mg of total
pLKO containing the specific construction SOCS-1, 750 ng of psPAX
(packing), 250 ng of pMD2G (viral envelope), and 7 × 105 HEK-293
cells were plated on 12-well plates with Dulbecco modified Eagle me-
dium (Invitrogen) supplemented with 20% FCS, at a confluence of
60% to 80% at 37°C and 5% CO2. After 16 hours, the supernatant
was removed, and the viral particles were stored at −80°C.
Flow Cytometry Analysis of Growth Factor Receptors
The tumor cells (106 cells in suspension) were fixed and treated with
PBS containing 1% paraformaldehyde, 0.5% saponin, 1% BSA, and
1% mouse serum for 20 minutes at 4°C. Cells were washed in buffer
A (PBS containing 0.5% saponin, 1% BSA, and 1%mouse serum) and
incubated in the same buffer with antibodies to Insulin-Rα, Insulin-
Rβ, epidermal growth factor receptor (EGFR), p-EGFR, and fibroblast
growth factor receptors 3, 4, and 5 (FGFR-3, -4, and -5; Santa Cruz
Biotechnology, Santa Cruz, CA) for 1 hour at 4°C, washed again, and
incubated with anti–rabbit Ig conjugated with a fluorochrome (phyco-
erythrin) for 1 hour at 4°C. Cells were washed twice with buffer A and
fixed with 0.4% paraformaldehyde. Fluorescence was measured on a
FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ), and
data were analyzed by FlowJo software (TriStar, Ashland, OR).
Cell Cycle Phases
The tumor cells (106 cells in suspension) were fixed and treated
with PBS containing 2% of paraformaldehyde for 15 minutes at 4°C
on a rotating table. Cells were washed three times with PBS and resus-
pended in 1 ml of 70% ethanol in PBS for 1 hour on ice. After further
102 SOCS-1 on Melanoma Cell Growth and Development Scutti et al. Translational Oncology Vol. 4, No. 2, 2011
washing in PBS, cells were resuspended in 1 ml of DNA staining
solution (2.5 μg/ml propidium iodide and 0.5 mg/ml RNase A in
PBS) and examined on a FACScan flow cytometer (BD Biosciences).
Data were analyzed by CellQuest software (Becton Dickinson, San
Jose, CA).
Fluorescence Microscopy with 4′,6-Diamidino-2-phenylindole
and Phalloidin
To evaluate the morphology of the cell lines, 2 × 104 cells were
seeded on sterilized round coverslips (Fisher Scientific Co, Pittsburgh,
PA) inserted into 24-well plates and allowed to reach 80% confluence.
After incubation, the coverslips were washed with PBS 1×, and cells
were fixed with 2% of cold paraformaldehyde for 30 minutes. The
cells were washed again and permeabilized with 0.1% Triton X-100
in PBS for 40 minutes. Cells were washed again and incubated with
phalloidin-tetramethyl rhodamine isothiocyanate (1:1000; Invitrogen)
and 1 mg/ml of 4′,6-diamidino-2-phenylindole (DAPI) diluted in PBS
for 1 hour. Coverslips were anchored onto slides in the presence of 4 μl
of Vectashield (Sigma), and nuclear and cytoplasm sizes and mor-
phology were observed in a fluorescence microscope at 60× magnifica-
tion in oil. DAPI staining (blue) was observed at 350 nm excitation
and 470 nm emission, and fluorescein isothiocyanate (red) was ob-
served at 490 and 520 nm, respectively. To phalloidin-TRITC (red
actin), a filter was used, at 580 nm excitation and 604 nm emission.
The nuclear areas of cells were calculated as in ellipsoids, as πD/2d/2,
taking D (long) and d (short) as diameters.
Monolayer Wound Healing Assay
The tumor cells (B16, B16 LVc, and B16 shR-SOCS-1), 5 × 105,
were seeded in six-well plates and allowed to reach complete conflu-
ence. To make the wound, the growth medium was aspirated and re-
placed by calcium-free PBS. A blue plastic P1000 pipette tip was used
to scratch the cell monolayer off, to create a clear area. Fresh medium
was added, and the wounds were observed using a phase-contrast
microscope. Images were taken at regular intervals up to 24 hours
and were analyzed by digitally drawing lines (using Adobe Photoshop)
and averaging the positions of the migrating cells at the edges.
Invasion Assay through Matrigel
The invasion assay was performed using BioCoat Matrigel invasion
chambers (BD Biosciences) primed according to the manufacturer’s
directions. A total of 5 × 103 tumor cells were used in this experiment.
A solution of 20% FBS in RPMI 1640 or RPMI 1640 was placed in
the lower well to act as a chemoattractant. Serum-free medium was
added on the upper chamber of the Matrigel plate, and cells were
incubated at 37°C for 24 hours. Invading cells detected on the bottom
of the filter were stained with Protocol Hema3 stain set (Fisher
Scientific). Cells unable (upper surface of filter) to invade the mem-
brane were removed with a swab. Samples were analyzed in a Nikon
Microphot-FXA microscope (Nikon, Inc, Melville, NY) at 10×, pic-
tures were taken using Leica DFC 320 R2 (Leica Microsystems,
Richmond, IL), and images were evaluated by Photoshop. Data are
expressed as the average number of cells from four fields on the lower
filter membrane surface.
Clonogenic Assay
The tumor cells (5 × 103) from each line were plated on 1% aga-
rose medium, and diluted in RPMI 1640 plus 20% FCS. Thirty days
after plating, the ability of the different cell lines to form colonies
reflected resistance to anoikis and potential malignance. Colonies
were counted with an optical microscope.
Western Blot Analysis
Cell lysates were prepared by sonication, and the SOCS-1 and actin
were detected in 30 μg of total protein by 10% SDS-PAGE and trans-
ferred to a membrane (Millipore, Billerica, MA) for immunoblot anal-
ysis. The membranes were washed in Tris-buffered saline with Tween
20 (10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20)
and blocked with 5% skim milk in Tris-buffered saline with Tween 20
overnight at 4°C with shaking. The blots were then probed overnight
at 4°C with primary antibodies for detection of murine α-SOCS-1 at
3 μg/ml (Invitrogen). After 2 hours of incubation with 1:1000 mouse
peroxidase–conjugated secondary antibody (Invitrogen), the immuno-
reactive proteins were detected by enhanced chemiluminescence using
the ECL detection system (GE Healthcare).
Messenger RNA Quantification
Total RNA was isolated using TRIzol (Invitrogen). To eliminate
DNA contamination, total RNA was treated with DNase I (Sigma-
Aldrich) before reverse transcription (RT). RT was performed using
a SuperScript II (Gibco BRL, San Diego, CA) and dT-primer follow-
ing the manufacturer’s protocol. For quantitative mRNA expression
analysis, real-time polymerase chain reaction (PCR) was carried out
with total complementary DNA using ABI Prism 7700 Sequence
Detector (Applied Biosystems, San Diego, CA). The sequences of the
primers (SOCS-1 and HPRT) used for amplification were as follows:




Amplified products were detected online through intercalation of the
fluorescent dye SYBR green (LightCycler-FastStart DNA Master
SYBR Green I Kit; Roche Diagnostics, Indianapolis, IN). The con-
ditions used were as follows: initial enzyme activation at 95°C for
10 minutes, followed by 55 cycles at 95°C for 10 seconds, 60°C for
5 seconds, and 72°C for 15 seconds. Gene-specific fluorescence was
measured at 72°C. The mRNA expression of target genes was nor-
malized by using the mRNA level of HPRT.
Cell Proliferation
The tumor cells (5 × 104) of each cell line were seeded in Petri
dishes for measuring the growth kinetics after 0, 24, 48, 72, 96,
and 120 hours. The cells were collected in PBS–0.02% EDTA resus-
pended in serum-free RPMI, and 20 μl of this suspension was used
for cell counting in a Neubauer chamber. The counting was per-
formed in triplicate using Trypan blue exclusion for viable cells.
Animals and Tumor Development In Vivo
Male C57Bl/6 mice (CEDEME, UNIFESP), 6 to 8 weeks old,
were housed under specific pathogen-free conditions. When subcuta-
neously challenged with B16F10-Nex2 melanoma cells, animals were
killed when tumors reached a maximum of 3000 mm3. Subcutaneous
challenges were made with 5 × 104 tumor cells of each cell line (95%
viability by Trypan blue exclusion test) in 0.2 ml of buffered saline
into the right flank of each mouse (n = 6 per group). Tumor growth
was recorded with a caliper and calculated as V = 0.52 × d2 × D
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(D, long diameter; d, short diameter). In the metastatic model, 5 ×
105 tumor cells of each cell line were injected into the tail veins of
mice (0.1 ml per mouse). Fifteen days later, mice (n = 5 per group)
were killed, their lungs were harvested, and the number of macro-
scopic tumor nodules were counted. All experiments with animals
were approved by the ethical committee of the Federal University
of São Paulo.
Statistical Analyses
Data presented as means ± SEs were compared by two-sided Stu-
dent’s t test or by analysis of variance, and when appropriate, we used
the Instat software version 3.05 (GraphPad, San Diego, CA). Real-
time PCR was analyzed by REST 2008, and data were considered
statistically significant when P < .05.
Results
SOCS-1 Expression in B16F10-Nex2 Melanoma Cells
RT-PCR and Western blot analyses showed that the cell lines B16
LVc and B16 expressed SOCS-1 constitutively, whereas SOCS-1 ex-
pression in B16 shR-SOCS-1 was much reduced. The relative ex-
pression of SOCS-1 in these cell lines compared with the total
expression in B16 (B16F10-Nex2 cells) is shown in Figure 1A.
The expression of SOCS-1 protein (25 kDa) was silenced in the
shRNAi-transduced cells (Figure 1B). Silencing of 83% relative to
the control was normalized using the housekeeping gene HPRT
and the method 2−ΔΔC t, with software REST 2008 based on their
Web site: http://www.gene-quantification.de/pfaffl-et-al-nar-2002.pdf.
Silencing of SOCS-1 Inhibits Tumor Cell Migration
and Invasion
Cell migration was measured using a monolayer wound healing
assay observed by phase-contrast microscopy with an inverted micro-
scope. Images were taken at regular intervals during the course of 0
to 24 hours of both areas flanking the wound and the marker lines
(=10 images). The cells silenced for SOCS-1 (B16 shR-SOCS-1)
showed reduced migration, roughly one third of the control (Figure 2A).
Furthermore, B16 shSOCS-1 significantly reduced the invasion when
compared with the cell lines B16 LVc and B16 as demonstrated in
Figure 2B.
SOCS-1 Acts as a Modulator of Resistance to Anoikis
As shown in Figure 3, the silencing of SOCS-1 abolished the capac-
ity of melanoma cells to grow in soft agar, thus independently of sub-
strate and cell-cell adhesion, which is a characteristic of metastatic
tumor cells. SOCS-1 and the network of cell reactivity that includes
this regulator then seem essential to determine resistance to anoikis.
Proliferation Rate of Tumor Cells Depends on
SOCS-1 Expression
In growth curve assays, melanoma cells duplicated every 24 hours.
Tumor cells with silenced SOCS-1 expression had a similar growth
Figure 1. The effectiveness of shRNAi silencing of SOCS-1 pro-
tein. (A) RT-PCR showing 83% reduction in SOCS-1 expression
in B16 shR-SOCS-1 transduced cells compared with the original
B16F10-Nex2 cell line, a derived clone (B16), and the cell line trans-
duced with the empty (control) lentivirus vector (B16 LVc). (B)
Western blot analysis showing the reduced expression of SOCS-1
in B16F10-Nex2 cell line stably transduced with shRNAi compared
with control cell lines. α-Actin was used as the constitutive expres-
sion control.
Figure 2. The silencing of SOCS-1 decreases cell motility and inva-
sion of melanoma cells. (A) By using the wound healing assay on
monolayers of 5 × 105 cells, the percent migrations of B16, B16
LVc, and B16 shR-SOCS-1 were 63%, 75%, and 28% respectively.
(B) The invasive properties of cell lines were measured in a Matrigel-
coated filter chamber assay. The values were 89.58%, 91.8%, and
39.5% for B16 LVc, B16, and B16 shR-SOCS-1, respectively, in three
independent experiments.
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rate up to 72 hours, but this was delayed with time, being significantly
reduced after 120 hours (Figure 4).
SOCS-1 Affects the Cell Cycle with Prolonged S Phase and
Cell Division
Differences in the growth rate could reflect alterations in the cell
cycle and in the expression of growth factor receptors. The cell cycles
of the different cell lines were evaluated by FACS. As shown in
Figure 5A, the silencing of SOCS-1 protein affected the cell cycle
expanding the S phase. Prolonged DNA replication, hence of cell
division, was reflected in the increased area of nuclei and cytoplasm
(Figure 5, B and C ). These results are coherent with the reduced
growth rate in the shR-SOCS-1 cell line.
Silencing of SOCS-1 Protein Promotes Down-regulation of
Growth Factor Receptors
Different receptor tyrosine kinases responding to insulin and
growth factors were downregulated in melanoma cells after SOCS-1
silencing. This was assessed by determining the frequency of cells
expressing tyrosine kinase receptors (TKRs) in the different cell lines
including shR-SOCS-1. Specific antibodies were used for insulin recep-
tor α and β chains, EGFR and phosphorylated EGFR, and three dif-
ferent FGFRs. As shown in Figure 6, shR-SOCS-1 showed, in
comparison with the control cell lines, a significant down-regulation
of TKRs particularly of p-EGFR, Ins-Rα, and FGFR-4 and -5. Signal-
ing involving these TKRs modulates DNA synthesis, cell proliferation,
migration, adhesion, metastasis, and survival.
Silencing SOCS-1 Inhibited Tumor Growth and Metastasis of
Melanoma In Vivo
The tumorigenic and metastatic potentials of melanoma cells in vivo
were virtually abolished by SOCS-1 silencing. All cell lines were
injected subcutaneously into male C57Bl/6 mice, but although B16
and B16 LVc cells formed tumors of comparable size, the shR-SOCS-1
cell line was unable to grow in vivo (Figure 7A). Animal survival was also
evaluated as shown in Figure 7B. With the control cell lines, all animals
were dead or killed with tumors of maximum 3000 mm3 before the
25th day of challenge. Two animals in the shR-SOCS-1 group died,
but four were alive and tumor-less up to 70 days after challenge, when
the experiment was terminated.
In the metastatic model, SOCS-1 protein silencing in melanoma
cells gave rise to a limited number of lung metastases in mice (average
of 75 nodules) when compared with B16 LVc and B16 cell lines
(Figure 8A ) that formed black masses of tumor growth in the lungs
approximately three times that of tumor-less lungs (Figure 8, B and C ).
Discussion
The evidence for the expression and functional activity of SOCS-1 in
tumor cells is controversial. At the protein level, SOCS-1 is undetect-
able in normal humanmelanocytes andmelanocytic nevi but uniformly
expressed in melanoma cell lines [26]. Moreover, detection of SOCS-1
by immunohistochemistry was closely related to tumor invasiveness,
thickness, and stage. Therefore, SOCS-1 was regarded as a progression
marker of human melanoma and a component of tumor resistance
against endogenous and/or administered cytokines. Aberrant expression
of SOCS-1 in melanoma cells may promote cell proliferation and pro-
tect tumor cells against IFN-γ released in the microenvironment.
Compared with normal breast cells, a high constitutive expression
of SOCS 2, 3, 5, 6, 7, CIS, and/or SOCS 1 genes was observed in
human cancer cells [27]. In the MCF-7 and HCC1937 cell lines, the
transcription of SOCS-1 was upregulated by IFN-α and/or ionizing
radiation. In breast cancer cells, STAT3 pathway is constitutively
activated, but the elevated expression of SOCS genes may confer
resistance to proinflammatory cytokines by shutting down STAT1/
STAT5 signaling.
Although SOCS-1 is also expressed in human prostate cancer both
in vitro and in vivo, it exerts growth-inhibitory function by down-
regulating cyclins D1 and E and cyclin-dependent kinases 2 and 4
[28]. In a brain metastatic melanoma cell line, the expression of
SOCS-1 was reduced relative to that of the parental cell and the
decreased SOCS-1 expression resulted in increased activation of
Figure 3. SOCS-1 protein is necessary for anoikis resistance: The
silencing of SOCS-1 inhibits tumor cells resistance to anoikis as
determined in a clonogenic assay. **P < .05. Results average
three independent experiments.
Figure 4.Melanomacell growth kinetics depends onSOCS-1. In vitro,
melanoma cells duplicate every 24 hours. Tumor cells with silenced
SOCS-1 expression showed a similar growth rate up to 72 hours,
but this was delayed with further incubation, being significantly
reduced after 120 hours. *P < .05. B16 LVc (gray bars), B16 (black
bars), and B16 shR-SOCS-1 (white bars). Results average three
independent experiments.
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STAT3 and overexpression of matrix metalloproteinase-2, basic fibro-
blast growth factor, and vascular endothelial growth factor, which
promoted brain metastasis coherent with enhanced invasion and
angiogenesis of melanoma cells [19]. These apparently contradictory
effects suggest that SOCS-1 and other SOCS have different functions
depending on the origin of the tumor.
In the present work, a stable system of SOCS-1 gene silencing using
lentiviral particles was performed creating a variant of B16F10-Nex2
melanoma cell that was tested in vitro and in vivo. Generally, SOCS-1
silencing rendered cells with loss of function regarding cell proliferation,
migration, invasion, tumor establishment in vivo, and tumor metastasis.
In opposition to this response, methylation-dependent silencing of
Figure 5. Silencing of SOCS-1 prolongs the S phase in the cell cycle. (A) Cell cycle phases of tumor cell lines are shown by FACScan flow
cytometerwith percent values. (B) Tumor cells (2×104)were seededonsterilized round coverslips, permeabilized, and stainedwith phalloidin-
TRITC (1:1000) and 1mg/ml ofDAPI diluted in PBS for 1 hour. The cells and nuclei of B16 shR-SOCS-1 cells have increased size comparedwith
the control tumor cells. (C) Means of nuclear areas in the cell lines were calculated using two nuclear diameters (A = πD/2d/2).
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Figure 6. Melanoma growth factor receptors. Cell lines (106 cells in suspension) were fixed and analyzed by FACScan flow cytometry
with antibodies specific for growth factor receptors. Data show the percent positive cells in 5 × 104 cells of B16 (black bars), B16 LVc
(gray bars), and B16 shR-SOCS-1 (white bars) cell lines.
Figure 7. Silencing of SOCS-1 renders cells unable to grow in vivo. (A) In the subcutaneousmodel, tumors were produced by injecting 5 ×
104 cells of each lineage into the right flanks of mice (n= 6, per cell line). The mean tumor volume of B16 shR-SOCS-1 was only 175 mm3.
(B) SOCS-1 silencing rendered cells of low aggressiveness with four of six tumor-free animals after 60 days of challenge.
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SOCS-3 and, to a lesser extent, the SOCS-1 gene in head and neck
squamous cell and Barrett adenocarcinoma was associated with tumor
growth in vitro and in vivo [30,31]. Also, the high frequency (65%) of
aberrant SOCS-1 methylation in human hepatocellular carcinoma and
the growth suppression caused by apoptosis on restoration in HCC cell
lines of SOCS-1 points to the importance of the constitutive activation
of the JAK/STAT pathway in tumor development [21].
In an attempt to understand the response of B16F10-Nex2 cells in
the face of SOCS-1 silencing in vitro and in vivo, we focused on the
growth control of melanoma cells. In comparison with normal mela-
nocytes, melanoma cells are additionally stimulated by EGF/trans-
forming growth factor α and nerve growth factor [32]. Other studies
have shown that insulin and insulin growth factor stimulate melanoma
cell growth, both in vivo and in vitro [33,34]. Insulin-resistant lines
showed defective insulin receptor because of ATP-dependent partial
proteolysis of the β subunit [35].
In the present work, we show that SOCS-1 silencing affected the
expression of insulin receptor α-chain, EGFR (phosphorylated), and
FGFR-4 and -5. There is evidence that SOCS-1 and SOCS-3 bind
to EGFR and associate with insulin receptor substrates 1 and 2. In
both cases, however, such interaction was regulatory. In the case of
EGFR binding, SOCS proteins facilitated proteasomal degradation
of the receptor [36]. As to the second interaction, SOCS-1 deficiency
increased IRS-2 expression and enhanced hepatic insulin sensitivity
in vivo [37]. In rat chondrosarcoma cells, however, binding of SOCS-1
to FGFR3 prolonged the half-life of the receptor, showing that it inhib-
ited FGFR3 degradation possibly by recycling it to the plasma mem-
brane [38]. Further, in this case, constitutive binding of SOCS-1 to
FGFR3 changed the balance between STAT-1 and MAPK pathways,
attenuating the former and enhancing the latter by extending the du-
ration of the signal. It was suggested that SOCS-1 is not an exclusive
signal inhibitor and may prolong MAPK signaling as described for
SOCS-3 that binds to RasGAP [39]. A similar signaling could be
operating in B16F10-Nex2 cells so that SOCS-1 silencing could be
followed by increased degradation of insulin receptor, EGFR, and
FGFR, leading to attenuation of the MAPK signaling that regulates
downstream kinases or transcription factors, the phosphatidylinositol-3
kinase, and Akt antiapoptotic pathway. MAPK leads to the transcription
of genes that are important for the cell cycle. Therefore, attenuation of
MAPK signaling would be compatible with alterations in the cell cycle
S phase, decreased proliferation, and decreased resistance to anoikis as
observed in the present work.
The effects of SOCS-1 silencing in vitro clearly reflect on the loss
of tumorigenesis in vivo as observed in B16F10-Nex2 cells, suggest-
ing that this protein could be a target of chemotherapy depending on
the cancer type and on the specific addressing of anti–SOCS-1 agents
to the tumor cells.
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